Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1HER2-positive Gastric Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Nivolumab 2toripalimab 1pemigatinib 1pembrolizumab 1enfortumab vedotin 1disitamab vedotin 1avelumab 1Specimen Handling 1Single Person 1Radiotherapy 1Mitomycin 1Magnetic Resonance Spectroscopy 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Transitional Cell × disitamab vedotin × Clear all
NCT05912205 2023-06-22

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡